Howard E Gendelman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6142967/publications.pdf

Version: 2024-02-01

410 papers	26,175 citations	4658 85 h-index	10734 138 g-index
429 all docs	429 docs citations	429 times ranked	24415 citing authors

#	Article	IF	Citations
1	Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. International Journal of Infectious Diseases, 2022, 114, 45-50.	3.3	11
2	Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy. Methods in Molecular Biology, 2022, 2407, 429-445.	0.9	3
3	Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. AIDS Reviews, 2022, 24, .	1.0	21
4	Prodrug Therapies for Infectious and Neurodegenerative Diseases. Pharmaceutics, 2022, 14, 518.	4.5	3
5	Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis. ACS Chemical Neuroscience, 2022, 13, 1232-1244.	3.5	16
6	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. Future Microbiology, 2022, 17, 887-897.	2.0	6
7	Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. Nature Communications, 2022, 13, .	12.8	21
8	Interleukin-2 expands neuroprotective regulatory T cells in Parkinsonâ€™s disease. , 2022, .		3
9	Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease. Clinical and Translational Medicine, 2022, 12, .	4.0	11
10	Development of an extended half-life GM-CSF fusion protein for Parkinson's disease. Journal of Controlled Release, 2022, 348, 951-965.	9.9	10
11	Alzheimerâ€™s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain, 2021, 144, 288-309.	7.6	132
12	Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs. Nanotheranostics, 2021, 5, 417-430.	5.2	0
13	Diagnostics for SARS-CoV-2 infections. Nature Materials, 2021, 20, 593-605.	27.5	533
14	A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention. Journal of NeuroImmune Pharmacology, 2021, 16, 270-288.	4.1	30
15	Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles. Antiviral Research, 2021, 187, 104975.	4.1	4
16	Nanocarrier vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 171, 215-239.	13.7	66
17	Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease. Biomaterials, 2021, 272, 120786.	11.4	26
18	Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissue. Aids, 2021, 35, 1733-1741.	2.2	2

#	Article	IF	Citations
19	Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease. EBioMedicine, 2021, 67, 103380.	6.1	23
20	The Immunopathobiology of SARS-CoV-2 Infection. FEMS Microbiology Reviews, 2021, 45, .	8.6	9
21	Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nature Communications, 2021, 12, 3453.	12.8	29
22	Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology, 2021, 18, 13.	2.0	20
23	Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment. Molecular Neurobiology, 2021, 58, 5703-5721.	4.0	12
24	Recovery of Latent HIV-1 from Brain Tissue by Adoptive Cell Transfer in Virally Suppressed Humanized Mice. Journal of NeuroImmune Pharmacology, 2021, 16, 796-805.	4.1	7
25	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. Nature Communications, 2021, 12, 5458.	12.8	26
26	Pharmacotherapeutics of SARS-CoV-2 Infections. Journal of NeuroImmune Pharmacology, 2021, 16, 12-37.	4.1	4
27	Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions. Frontiers in Immunology, 2021, 12, 741502.	4.8	28
28	CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination. EBioMedicine, 2021, 73, 103678.	6.1	23
29	CD4+ effector T cells accelerate Alzheimerâ€™s disease in mice. Journal of Neuroinflammation, 2021, 18, 272.	7.2	48
30	The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings. Journal of NeuroImmune Pharmacology, 2021, 16, 706-717.	4.1	1
31	A Link Between Methylglyoxal and Heart Failure During HIV-1 Infection. Frontiers in Cardiovascular Medicine, 2021, 8, 792180.	2.4	3
32	CD4+ T cell effector activities accelerate Alzheimer's disease pathologies.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052738.	0.8	0
33	Synthesis and Characterization of Long-Acting Darunavir Prodrugs. Molecular Pharmaceutics, 2020, 17, 155-166.	4.6	11
34	Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics, 2020, 10, 630-656.	10.0	27
35	Predictive biomarkers for cognitive decline during progressive HIV infection. EBioMedicine, 2020, 51, 102538.	6.1	4
36	Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking. Biomaterials, 2020, 231, 119669.	11.4	16

#	Article	IF	Citations
37	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. Journal of NeuroImmune Pharmacology, 2020, 15, 359-386.	4.1	391
38	Elucidating the pathogenic mechanisms of AD brainâ€derived, tauâ€containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons. Alzheimer's and Dementia, 2020, 16, e037316.	0.8	1
39	HIV-1-Associated Left Ventricular Cardiac Dysfunction in Humanized Mice. Scientific Reports, 2020, 10, 9746.	3.3	5
40	Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Molecular Neurodegeneration, 2020, 15, 32.	10.8	57
41	Amplification of Replication Competent HIV-1 by Adoptive Transfer of Human Cells From Infected Humanized Mice. Frontiers in Cellular and Infection Microbiology, 2020, 10, 38.	3.9	7
42	Neuroprotective Activities of Long-Acting Granulocyteâ€“Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice. Neurotherapeutics, 2020, 17, 1861-1877.	4.4	17
43	Pathways towards human immunodeficiency virus elimination. EBioMedicine, 2020, 53, 102667.	6.1	12
44	Immunotherapy for Parkinsonâ€™s disease. Neurobiology of Disease, 2020, 137, 104760.	4.4	57
45	A year-long extended release nanoformulated cabotegravir prodrug. Nature Materials, 2020, 19, 910-920.	27.5	66
46	Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues. Alzheimer's and Dementia, 2020, 16, 896-907.	0.8	105
47	A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102185.	3.3	12
48	SARS-CoV-2 Infection Leads to Neurological Dysfunction. Journal of NeuroImmune Pharmacology, 2020, 15, 167-173.	4.1	78
49	JNIP Impact Factor Rise Is a Final Tribute to the Years of Impactful Service Made by our Managing Editor. Journal of NeuroImmune Pharmacology, 2020, 15, 341-342.	4.1	0
50	Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases. , 2020, , 335-370.		0
51	Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress. Molecular Neurobiology, 2019, 56, 2896-2907.	4.0	18
52	Synthesis of a long acting nanoformulated emtricitabine ProTide. Biomaterials, 2019, 222, 119441.	11.4	15
53	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nature Communications, 2019, 10, 2753.	12.8	222
54	A long acting nanoformulated lamivudine ProTide. Biomaterials, 2019, 223, 119476.	11.4	24

#	Article	IF	Citations
55	Creation of a long-acting rilpivirine prodrug nanoformulation. Journal of Controlled Release, 2019, 311-312, 201-211.	9.9	22
56	A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinsonâ€™s Disease. Frontiers in Cellular Neuroscience, 2019, 13, 421.	3.7	32
57	Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation . International Journal of Nanomedicine, 2019, Volume 14, 6231-6247.	6.7	16
58	Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases. Drug Discovery Today, 2019, 24, 873-882.	6.4	51
59	Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice. Molecular Neurodegeneration, 2019, 14, 12.	10.8	53
60	In Appreciation for a Job Well Done!. Journal of NeuroImmune Pharmacology, 2019, 14, 1-1.	4.1	1
61	Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice. Frontiers in Immunology, 2019, 10, 340.	4.8	20
62	The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture. Trends in Microbiology, 2019, 27, 593-606.	7.7	29
63	Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages. Journal of NeuroImmune Pharmacology, 2019, 14, 44-51.	4.1	6
64	Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques. Aids, 2019, 33, 585-588.	2.2	8
65	J-109â€ƒSequential administration of LASER ART and CRISPR-Cas9 can facilitate HIV-1 elimination in humanized mice. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 55-55.	2.1	1
66	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 564-571.	5.6	20
67	Neurotheranostics as personalized medicines. Advanced Drug Delivery Reviews, 2019, 148, 252-289.	13.7	63
68	HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication. Journal of NeuroImmune Pharmacology, 2019, 14, 52-67.	4.1	31
69	Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 272-280.	2.5	9
70	Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Journal of NeuroVirology, 2018, 24, 398-410.	2.1	11
71	Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 521-531.	2.8	28
72	Creation of a long-acting nanoformulated dolutegravir. Nature Communications, 2018, 9, 443.	12.8	101

#	Article	IF	Citations
73	Broad-spectrum antivirals. Nature Materials, 2018, 17, 114-116.	27.5	7
74	Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 248-259.	2.8	13
75	Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine, 2018, 13, 871-885.	3.3	21
76	Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimerâ€™s disease mice. Journal of Neuroimmunology, 2018, 319, 80-92.	2.3	53
77	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 2018, 151, 53-65.	11.4	77
78	Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	30
79	P1â€025: EXOSOMES CONTAINING SPECIFIC TAU OLIGOMER FORMATIONS ACCELERATE PATHOLOGICAL TAU PHOSPHORYLATION IN C57BL/6 MICE. Alzheimer's and Dementia, 2018, 14, P275.	0.8	1
80	P-A9 Transformation of Darunavir into a long acting nanoformulated prodrug. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 55-55.	2.1	0
81	P-A8 Establishing tissue reservoirs for the human immunodeficiency virus in humanized mice. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 55-55.	2.1	0
82	O2â€01â€02: CHARACTERIZATION OF HUMAN ALZHEIMER'S DISEASE BRAINâ€DERIVED EXOSOMES. Alzheimer's and Dementia, 2018, 14, P608.	0.8	1
83	Biodegradable polyanhydrideâ€based nanomedicines for blood to brain drug delivery. Journal of Biomedical Materials Research - Part A, 2018, 106, 2881-2890.	4.0	19
84	Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials, 2018, 185, 174-193.	11.4	27
85	Neuropathogenesis of human immunodeficiency virus infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 152, 21-40.	1.8	31
86	EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. PLoS Pathogens, 2018, 14, e1007061.	4.7	51
87	Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics, 2018, 8, 256-276.	10.0	40
88	ProTide generated long-acting abacavir nanoformulations. Chemical Communications, 2018, 54, 8371-8374.	4.1	17
89	D-110 Synergism between CRISPR/Cas9 and LASER ART leads to elimination of HIV-1 with no rebound in Humanized Mice. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 42-42.	2.1	0
90	URMC-099 facilitates amyloid-Î² clearance in a murine model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2018, 15, 137.	7.2	36

#	Article	IF	Citations
91	Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinsonâ€™s disease. Molecular Neurodegeneration, 2018, 13, 26.	10.8	39
92	Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine, 2018, 13, 2139-2154.	3.3	9
93	Long-Acting Nanoformulated Antiretroviral Therapy. , 2018, , 1211-1220.		0
94	Control of Neuroinflammation for Therapeutic Gain. , 2017, , 971-978.		0
95	Long-acting slow effective release antiretroviral therapy. Expert Opinion on Drug Delivery, 2017, 14, 1281-1291.	5.0	53
96	The cortical signature of symptom laterality in Parkinson's disease. NeuroImage: Clinical, 2017, 14, 433-440.	2.7	51
97	Creation of a Long-Acting Nanoformulated 2â€²,3â€²-Dideoxy-3â€²-Thiacytidine. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e75-e83.	2.1	41
98	P-D5 Synthesis and characterization of core-â€“shell silica cobalt ferrite nanoparticles as a first step towards developing ultrasensitive MRI probes for long-acting antiretroviral drug biodistribution testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 91.	2.1	1
99	Cathepsin B Improves ÃŸ-Amyloidosis and Learning and Memory in Models of Alzheimerâ€™s Disease. Journal of NeuroImmune Pharmacology, 2017, 12, 340-352.	4.1	51
100	A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology, 2017, 14, 17.	2.0	94
101	Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. Acta Biomaterialia, 2017, 49, 507-520.	8.3	28
102	Overview of Mononuclear Phagocytes. , 2017, , 141-153.		0
103	Macrophages, Microglia and Dendritic Cell Function. , 2017, , 155-166.		0
104	Immunotherapies for Movement Disorders: Parkinsonâ€™s Disease and Amyotrophic Lateral Sclerosis. , 2017, , 767-797.		1
105	T cells and Parkinson's disease. Lancet Neurology, The, 2017, 16, 769-771.	10.2	22
106	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinsonâ€™s disease trial. Npj Parkinson's Disease, 2017, 3, 10.	5.3	98
107	Proteomic analysis of mesenchymal to Schwann cell transdifferentiation. Journal of Proteomics, 2017, 165, 93-101.	2.4	21
108	Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. Nanomedicine, 2017, 12, 99-115.	3.3	76

#	Article	IF	Citations
109	Thank You!. Journal of NeuroImmune Pharmacology, 2017, 12, 565-565.	4.1	0
110	Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains. DMM Disease Models and Mechanisms, 2017, 10, 1489-1502.	2.4	15
111	Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. Journal of Clinical Investigation, 2017, 127, 857-873.	8.2	44
112	MEMRI is a biomarker defining nicotine-specific neuronal responses in subregions of the rodent brain. American Journal of Translational Research (discontinued), 2017, 9, 601-610.	0.0	7
113	Quiet connections: Reduced frontoâ€temporal connectivity in nondemented Parkinson's Disease during working memory encoding. Human Brain Mapping, 2016, 37, 3224-3235.	3.6	41
114	Neuropharmacologic Approaches to Restore the Brainâ€™s Microenvironment. Journal of NeuroImmune Pharmacology, 2016, 11, 484-494.	4.1	10
115	HIV-1 cellular and tissue replication patterns in infected humanized mice. Scientific Reports, 2016, 6, 23513.	3.3	59
116	The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-Î² degradation. Journal of Neuroinflammation, 2016, 13, 184.	7.2	22
117	Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine, 2016, 11, 1913-1927.	3.3	41
118	Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics, 2016, 13, 635-646.	4.4	24
119	Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2RÎ³ c null Mouse Brain Atlas. Journal of NeuroImmune Pharmacology, 2016, 11, 133-141.	4.1	2
120	The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 109-122.	3.3	27
121	Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Current Opinion in Pharmacology, 2016, 26, 87-95.	3.5	46
122	Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Molecular Neurobiology, 2016, 53, 3286-3297.	4.0	14
123	Long-Acting Nanoformulated Antiretroviral Therapy. , 2016, , 1-10.		1
124	Metabolic drift in the aging brain. Aging, 2016, 8, 1000-1020.	3.1	89
125	Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS ONE, 2015, 10, e0145966.	2.5	13
126	Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy. International Journal of Nanomedicine, 2015, 10, 3779.	6.7	17

#	Article	IF	Citations
127	A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders. Journal of NeuroImmune Pharmacology, 2015, 10, 645-650.	4.1	36
128	Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. Journal of Neuroscience, 2015, 35, 16463-16478.	3.6	68
129	Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 715-729.	3.3	46
130	Comprehensive bioimaging with fluorinated nanoparticles using breathable liquids. Nature Communications, 2015, 6, 5998.	12.8	50
131	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials, 2015, 41, 141-150.	11.4	58
132	Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages. Retrovirology, 2015, 12, 5.	2.0	33
133	Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Research, 2015, 120, 85-88.	4.1	23
134	Potential of N-acetylated-para-aminosalicylic acid to accelerate manganese enhancement decline for long-term MEMRI in rodent brain. Journal of Neuroscience Methods, 2015, 251, 92-98.	2.5	2
135	Granulocyte-Macrophage Colony Stimulating Factor Exerts Protective and Immunomodulatory Effects in Cortical Trauma. Journal of Neuroimmunology, 2015, 278, 162-173.	2.3	30
136	Presenilin-1 familial Alzheimerâ€™s disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice. Brain, Behavior, and Immunity, 2015, 49, 311-321.	4.1	15
137	Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 751-767.	3.3	98
138	AAV2/1 CD74 Gene Transfer Reduces Î²-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease. Molecular Therapy, 2015, 23, 1712-1721.	8.2	34
139	Influence of age, irradiation and humanization on NSG mouse phenotypes. Biology Open, 2015, 4, 1243-1252.	1.2	24
140	Nano-enabled delivery of diverse payloads across complex biological barriers. Journal of Controlled Release, 2015, 219, 548-559.	9.9	54
141	An interactive cluster heat map to visualize and explore multidimensional metabolomic data. Metabolomics, 2015, 11, 1029-1034.	3.0	39
142	Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine, 2014, 9, 1403-1422.	3.3	78
143	Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Molecular Neurodegeneration, 2014, 9, 58.	10.8	52
144	Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution. Nanomedicine, 2014, 9, 1341-1352.	3.3	11

#	Article	IF	Citations
145	Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations. Antimicrobial Agents and Chemotherapy, 2014, 58, 7510-7519.	3.2	21
146	Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Translational Neurodegeneration, 2014, 3, 25.	8.0	65
147	Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Current Opinion in HIV and AIDS, 2014, 9, 585-590.	3.8	15
148	Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson's disease: a pharmaco-magnetoencephalography study. Journal of Neurophysiology, 2014, 112, 1739-1747.	1.8	72
149	Fourth Annual Conference of the American Society for Nanomedicine. Journal of NeuroImmune Pharmacology, 2014, 9, 1-38.	4.1	2
150	Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine, 2014, 9, 501-516.	3.3	58
151	The promise of nanoneuromedicine. Nanomedicine, 2014, 9, 171-176.	3.3	12
152	Brain Region Mapping Using Global Metabolomics. Chemistry and Biology, 2014, 21, 1575-1584.	6.0	65
153	Longâ€acting antituberculous therapeutic nanoparticles target macrophage endosomes. FASEB Journal, 2014, 28, 5071-5082.	0.5	39
154	Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance. Journal of Virology, 2014, 88, 9504-9513.	3.4	48
155	Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine, 2014, 9, 469-485.	3.3	47
156	Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies. Current Medicinal Chemistry, 2014, 21, 4186-4198.	2.4	75
157	Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine, 2014, 9, 501-16.	3.3	36
158	Neuronanomedicine. Springer Protocols, 2014, , 223-231.	0.3	0
159	Centrifugal Elutriation for Studies of Neuroimmunity. Springer Protocols, 2014, , 165-175.	0.3	1
160	Cell-Based Drug Delivery for Improving Antiretroviral Therapeutic Outcomes. , 2014, , 529-546.		0
161	Nanomedicines for Nervous System Diseases. , 2014, , 2125-2156.		0
162	Bridge between neuroimmunity and traumatic brain injury. Current Pharmaceutical Design, 2014, 20, 4284-98.	1.9	45

#	Article	IF	Citations
163	Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. Journal of NeuroVirology, 2013, 19, 254-260.	2.1	14
164	Improved Visualization of Neuronal Injury Following Glial Activation by Manganese Enhanced MRI. Journal of NeuroImmune Pharmacology, 2013, 8, 1027-1036.	4.1	13
165	Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. Journal of NeuroImmune Pharmacology, 2013, 8, 1224-1238.	4.1	30
166	Enhancement of NMDA Receptor-Mediated Excitatory Postsynaptic Currents by gp120-Treated Macrophages: Implications for HIV-1-Associated Neuropathology. Journal of NeuroImmune Pharmacology, 2013, 8, 921-933.	4.1	13
167	GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. Journal of Neuroimmunology, 2013, 265, 1-10.	2.3	90
168	Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1263-1273.	3.3	83
169	Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2013, 57, 3110-3120.	3.2	70
170	CCL2 affects Î²-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1060-1068.	3.1	67
171	Immunoisolation of Nanoparticles Containing Endocytic Vesicles for Drug Quantitation. Methods in Molecular Biology, 2013, 991, 41-46.	0.9	5
172	Methods for Isolation and Identification of Nanoparticle-Containing Subcellular Compartments. Methods in Molecular Biology, 2013, 991, 47-55.	0.9	6
173	Functional Proteome of Macrophage Carried Nanoformulated Antiretroviral Therapy Demonstrates Enhanced Particle Carrying Capacity. Journal of Proteome Research, 2013, 12, 2282-2294.	3.7	20
174	Lipids and cognition make good bedfellows for neuroAIDS. Neurology, 2013, 81, 1480-1481.	1.1	2
175	Mouse brain fixation to preserve In vivo manganese enhancement for ex vivo manganeseâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2013, 38, 482-487.	3.4	13
176	Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine, 2013, 8, 1807-1813.	3.3	85
177	Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases. PLoS ONE, 2013, 8, e61852.	2.5	124
178	Neuroimmune Cross Talk and HIV-Associated Neurocognitive Disorders. , 2013, , 211-248.		0
179	Inflammation and Adaptive Immunity in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009381-a009381.	6.2	221
180	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. Aids, 2012, 26, 2135-2144.	2.2	121

#	Article	IF	Citations
181	Immunization strategies for Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, S218-S221.	2.2	26
182	Rodent models for HIV-associated neurocognitive disorders. Trends in Neurosciences, 2012, 35, 197-208.	8.6	66
183	Biochemical and Biologic Characterization of Exosomes and Microvesicles as Facilitators of HIV-1 Infection in Macrophages. Journal of Immunology, 2012, 189, 744-754.	0.8	198
184	A call for transparent reporting to optimize the predictive value of preclinical research. Nature, 2012, 490, 187-191.	27.8	1,055
185	A model of nitric oxide induced Î±-synuclein misfolding in Parkinson's disease. Neuroscience Letters, 2012, 523, 167-173.	2.1	38
186	Rapid and reliable quantitation of amino acids and myo-inositol in mouse brain by high performance liquid chromatography and tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 893-894, 15-20.	2.3	27
187	Changes in the plasma proteome follows chronic opiate administration in simian immunodeficiency virus infected rhesus macaques. Drug and Alcohol Dependence, 2012, 120, 105-112.	3.2	10
188	Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinsonâ€™s Disease. PLoS ONE, 2012, 7, e38113.	2.5	106
189	CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinsonâ€™s Disease. Journal of NeuroImmune Pharmacology, 2012, 7, 927-938.	4.1	255
190	Change in Evolution. Journal of NeuroImmune Pharmacology, 2012, 7, 715-716.	4.1	0
191	Plasma Proteomic Profiling in HIV-1 Infected Methamphetamine Abusers. PLoS ONE, 2012, 7, e31031.	2.5	19
192	Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. International Journal of Nanomedicine, 2012, 7, 2373.	6.7	48
193	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1â€“Infected Human Peripheral Blood Lymphocyteâ€“Reconstituted Mice. Journal of Infectious Diseases, 2012, 206, 1577-1588.	4.0	62
194	Can Humanized Mice Reflect the Complex Pathobiology of HIV-Associated Neurocognitive Disorders?. Journal of NeuroImmune Pharmacology, 2012, 7, 352-362.	4.1	27
195	Commentary: Animal Models of NeuroAIDS. Journal of NeuroImmune Pharmacology, 2012, 7, 301-305.	4.1	7
196	Murine Motor and Behavior Functional Evaluations for Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Intoxication. Journal of NeuroImmune Pharmacology, 2012, 7, 279-288.	4.1	26
197	Methamphetamine-Associated Psychosis. Journal of NeuroImmune Pharmacology, 2012, 7, 113-139.	4.1	202
198	Not Just Another Jigsaw Puzzle. Journal of NeuroImmune Pharmacology, 2012, 7, 1-2.	4.1	2

#	Article	IF	Citations
199	Macrophage Bridging Conduit Trafficking of HIV-1 Through the Endoplasmic Reticulum and Golgi Network. Journal of Proteome Research, 2011, 10, 3225-3238.	3.7	68
200	Pulsed Stable Isotope Labeling of Amino Acids in Cell Culture Uncovers the Dynamic Interactions between HIV-1 and the Monocyte-Derived Macrophage. Journal of Proteome Research, 2011, 10, 2852-2862.	3.7	20
201	Cell Delivery of Therapeutic Nanoparticles. Progress in Molecular Biology and Translational Science, 2011, 104, 563-601.	1.7	101
202	Cell-mediated drug delivery. Expert Opinion on Drug Delivery, 2011, 8, 415-433.	5.0	274
203	Neuroprotective activities of regulatory T cells. Trends in Molecular Medicine, 2011, 17, 687-688.	6.7	41
204	BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neuroscience, 2011, 180, 293-304.	2.3	9
205	Fusobacterium necrophorum causing infective endocarditis and liver and splenic abscesses. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2011, 53, 169-172.	1.1	16
206	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. International Journal of Nanomedicine, 2011, 6, 3393.	6.7	37
207	Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson?s Disease. Journal of Nanomedicine & Nanotechnology, 2011, 01, .	1.1	58
208	Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Journal of Controlled Release, 2011, 150, 204-211.	9.9	107
209	Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitisâ˜†. Journal of Neuroimmunology, 2011, 230, 33-41.	2.3	28
210	Proteomic biosignatures for monocyteâ€“macrophage differentiation. Cellular Immunology, 2011, 271, 239-255.	3.0	18
211	Human Immunodeficiency Virus type 1 Endocytic Trafficking Through Macrophage Bridging Conduits Facilitates Spread of Infection. Journal of NeuroImmune Pharmacology, 2011, 6, 658-675.	4.1	75
212	UPLCâ€“MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2332-2338.	2.3	33
213	Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice. Journal of Neuroscience, 2011, 31, 3148-3157.	3.6	110
214	Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. Nanomedicine, 2011, 6, 1215-1230.	3.3	67
215	Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine, 2011, 6, 975-994.	3.3	62
216	Pathways towards an effective immunotherapy for Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2011, 11, 1703-1715.	2.8	29

#	Article	IF	Citations
217	Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology, 2011, 5, 592-605.	3.0	26
218	Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs. Journal of Visualized Experiments, 2010, , .	0.3	17
219	Molecular mechanisms involving sigma receptorâ€“mediated induction of MCP-1: implication for increased monocyte transmigration. Blood, 2010, 115, 4951-4962.	1.4	115
220	Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring. Journal of Visualized Experiments, 2010, , .	0.3	3
221	Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics. Journal of NeuroImmune Pharmacology, 2010, 5, 592-601.	4.1	97
222	Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS. Journal of NeuroImmune Pharmacology, 2010, 5, 456-468.	4.1	48
223	Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. Journal of Controlled Release, 2010, 143, 290-301.	9.9	142
224	HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiology of Disease, 2010, 37, 542-548.	4.4	78
225	Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase. Neurotherapeutics, 2010, 7, 392-398.	4.4	11
226	Proteomic analyses of monocytes obtained from Hispanic women with HIVâ€associated dementia show depressed antioxidants. Proteomics - Clinical Applications, 2010, 4, 706-714.	1.6	22
227	Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. Journal of Neurochemistry, 2010, 114, 1261-1276.	3.9	36
228	Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinsonâ€™s Disease. Journal of Immunology, 2010, 184, 2261-2271.	0.8	346
229	CD8+ Cell Depletion Accelerates HIV-1 Immunopathology in Humanized Mice. Journal of Immunology, 2010, 184, 7082-7091.	0.8	80
230	Neuroprotective Activities of CEP-1347 in Models of NeuroAIDS. Journal of Immunology, 2010, 184, 746-756.	0.8	47
231	Neuroprotective Activities of CD4+CD25+ Regulatory T Cells. NeuroImmune Biology, 2010, 9, 197-210.	0.2	0
232	Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques. Journal of Proteome Research, 2010, 9, 4721-4731.	3.7	21
233	CNS expression of antiâ€inflammatory cytokine interleukinâ€4 attenuates Alzheimer's diseaseâ€like pathogenesis in APP+PS1 bigenic mice. FASEB Journal, 2010, 24, 3093-3102.	0.5	187
234	Functional Proteomic Analysis for Regulatory T Cell Surveillance of the HIV-1-Infected Macrophage. Journal of Proteome Research, 2010, 9, 6759-6773.	3.7	29

#	Article	IF	Citations
235	Macrophage delivery of therapeutic nanozymes in a murine model of Parkinsonâ€™s disease. Nanomedicine, 2010, 5, 379-396.	3.3	154
236	Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Experimental Neurology, 2010, 222, 1-5.	4.1	25
237	Links between Progressive HIV-1 Infection of Humanized Mice and Viral Neuropathogenesis. American Journal of Pathology, 2010, 177, 2938-2949.	3.8	94
238	CCL2 Accelerates Microglia-Mediated AÎ² Oligomer Formation and Progression of Neurocognitive Dysfunction. PLoS ONE, 2009, 4, e6197.	2.5	100
239	Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS. Journal of Immunology, 2009, 183, 661-669.	0.8	211
240	Neuromodulatory Activities of CD4+CD25+ Regulatory T Cells in a Murine Model of HIV-1-Associated Neurodegeneration. Journal of Immunology, 2009, 182, 3855-3865.	0.8	82
241	Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease. Antioxidants and Redox Signaling, 2009, 11, 2151-2166.	5.4	114
242	AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, Î²-amyloidosis, and Learning Impairment of APP/PS1 Mice. Molecular Therapy, 2009, 17, 803-809.	8.2	62
243	Registration of in vivo MR to histology of rodent brains using blockface imaging. Proceedings of SPIE, 2009, , .	0.8	5
244	Nitrated Î±-Synuclein-Induced Alterations in Microglial Immunity Are Regulated by CD4+ T Cell Subsets. Journal of Immunology, 2009, 182, 4137-4149.	0.8	177
245	Simvastatin Inhibits the Activation of p21^{ras}and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease. Journal of Neuroscience, 2009, 29, 13543-13556.	3.6	156
246	NanoART synthesis, characterization, uptake, release and toxicology for human monocyteâ€“macrophage drug delivery. Nanomedicine, 2009, 4, 903-917.	3.3	116
247	CD 4+ T cells in the pathobiology of neurodegenerative disorders. Journal of Neuroimmunology, 2009, 211, 3-15.	2.3	48
248	Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. Journal of Neuroimmunology, 2009, 213, 47-59.	2.3	24
249	HIV-1 transforms the monocyte plasma membrane proteome. Cellular Immunology, 2009, 258, 44-58.	3.0	25
250	Monocyte Chemotactic Protein-1 Regulates Voltage-Gated K+ Channels and Macrophage Transmigration. Journal of NeuroImmune Pharmacology, 2009, 4, 47-59.	4.1	44
251	4-Aminopyridine Improves Spatial Memory in a Murine Model of HIV-1 Encephalitis. Journal of NeuroImmune Pharmacology, 2009, 4, 317-327.	4.1	23
252	Lithium therapy for human immunodeficiency virus type 1â€“associated neurocognitive impairment. Journal of NeuroVirology, 2009, 15, 176-186.	2.1	90

#	Article	IF	Citations
253	A Coat of Many Colors: Neuroimmune Crosstalk in Human Immunodeficiency Virus Infection. Neuron, 2009, 64, 133-145.	8.1	110
254	NanoART, neuroAIDS and CNS drug delivery. Nanomedicine, 2009, 4, 557-574.	3.3	112
255	Neurodegenerative disorders and nanoformulated drug development. Nanomedicine, 2009, 4, 541-555.	3.3	61
256	Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells. Journal of Proteome Research, 2009, 8, 3497-3511.	3.7	78
257	Facilitated Monocyte-Macrophage Uptake and Tissue Distribution of Superparmagnetic Iron-Oxide Nanoparticles. PLoS ONE, 2009, 4, e4343.	2.5	116
258	Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities. Journal of NeuroImmune Pharmacology, 2008, 3, 59-74.	4.1	113
259	Opendra â€œBillâ€•Narayan (1936â€“2007): A Personal Tribute to a Friend, Teacher, and Colleague. Journal of NeuroImmune Pharmacology, 2008, 3, 1-4.	4.1	0
260	The Promise and Perils of CNS Drug Delivery: A Video Debate. Journal of NeuroImmune Pharmacology, 2008, 3, 58-58.	4.1	10
261	Disseminating Research Discovery Through an Interactive Video: a Paradigm Shift for Journal Publication. Journal of NeuroImmune Pharmacology, 2008, 3, 57-57.	4.1	0
262	HIV-1-Infected Astrocytes and the Microglial Proteome. Journal of NeuroImmune Pharmacology, 2008, 3, 173-186.	4.1	44
263	Modulation of innate immunity by copolymerâ€1 leads to neuroprotection in murine HIVâ€1 encephalitis. Glia, 2008, 56, 223-232.	4.9	18
264	Nitrated alphaâ€synucleinâ€activated microglial profiling for Parkinsonâ€™s disease. Journal of Neurochemistry, 2008, 104, 1504-1525.	3.9	195
265	Ingress of blood-borne macrophages across the blood-brain barrier in murine HIV-1 encephalitis. Journal of Neuroimmunology, 2008, 200, 41-52.	2.3	17
266	Erratum to â€œCSF proteomic fingerprints for HIV-associated cognitive impairmentâ€• Journal of Neuroimmunology, 2008, 205, 161.	2.3	0
267	Nitrated Î±â€“Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. PLoS ONE, 2008, 3, e1376.	2.5	311
268	Introducing Neuroimmune Pharmacology. , 2008, , 1-3.		0
269	Macrophages, Microglia, and Dendritic C. , 2008, , 89-104.		1
270	STAT1 signaling modulates HIV-1â€“induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood, 2008, 111, 2062-2072.	1.4	130

#	Article	IF	Citations
271	Proteomic Modeling for HIV-1 Infected Microglia-Astrocyte Crosstalk. PLoS ONE, 2008, 3, e2507.	2.5	46
272	Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice. PLoS ONE, 2008, 3, e2740.	2.5	174
273	The neuropathogenesis of HIVâ€1 infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 45-67.	1.8	11
274	Copolymer-1 Induces Adaptive Immune Anti-inflammatory Glial and Neuroprotective Responses in a Murine Model of HIV-1 Encephalitis. Journal of Immunology, 2007, 179, 4345-4356.	0.8	36
275	Human Immunodeficiency Virus Type 1 Pathobiology Studied in Humanized BALB/c-Rag2 â^'/â^' Î³ c â^'/â^' Mice. Journal of Virology, 2007, 81, 2700-2712.	3.4	130
276	Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 235-242.	2.1	19
277	Cytoskeletal Protein Transformation in HIV-1-Infected Macrophage Giant Cells. Journal of Immunology, 2007, 178, 6404-6415.	0.8	46
278	Selective inhibition of NF-ÎºB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18754-18759.	7.1	391
279	Interferon-Î³ and Tumor Necrosis Factor-Î± Regulate Amyloid-Î² Plaque Deposition and Î²-Secretase Expression in Swedish Mutant APP Transgenic Mice. American Journal of Pathology, 2007, 170, 680-692.	3.8	348
280	Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders. International Review of Neurobiology, 2007, 82, 297-325.	2.0	350
281	Cerebrospinal Fluid Proteomic Profiling of HIV-1-Infected Patients with Cognitive Impairment. Journal of Proteome Research, 2007, 6, 4189-4199.	3.7	95
282	A Macrophageâ^'Nanozyme Delivery System for Parkinson's Disease. Bioconjugate Chemistry, 2007, 18, 1498-1506.	3.6	177
283	Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinsonâ€™s disease. Journal of Leukocyte Biology, 2007, 82, 1083-1094.	3.3	323
284	T cell independent mechanism for copolymerâ€1â€induced neuroprotection. European Journal of Immunology, 2007, 37, 3143-3154.	2.9	62
285	HIV-1 gp120 Compromises Bloodâ€“Brain Barrier Integrity and Enhance Monocyte Migration across Bloodâ€“Brain Barrier: Implication for Viral Neuropathogenesis. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 123-134.	4.3	202
286	Novel Delivery System Enhances Efficacy of Antiretroviral Therapy in Animal Model for HIV-1 Encephalitis. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1033-1042.	4.3	67
287	Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2007, 100, 503-519.	3.9	115
288	Genomic and proteomic microglial profiling: pathways for neuroprotective inflammatory responses following nerve fragment clearance and activation. Journal of Neurochemistry, 2007, 102, 627-645.	3.9	64

#	Article	IF	Citations
289	Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology, 2007, 358, 148-158.	2.4	90
290	Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology, 2007, 363, 198-209.	2.4	72
291	Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiology of Disease, 2007, 26, 146-152.	4.4	44
292	Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinsonâ€™s disease. Neurobiology of Disease, 2007, 26, 590-596.	4.4	114
293	CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Journal of Neuroimmunology, 2007, 183, 60-68.	2.3	90
294	HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: New insights into bloodâ€“brain barrier dysfunction for HIV-1-associated dementia. Journal of Neuroimmunology, 2007, 185, 37-46.	2.3	63
295	CSF proteomic fingerprints for HIV-associated cognitive impairment. Journal of Neuroimmunology, 2007, 192, 157-170.	2.3	57
296	Biomarkers, Laboratory, and Animal Models for the Design and Development of Adjunctive Therapies for HIV-1 Dementia and other Neuroinflammatory Disorders. Journal of NeuroImmune Pharmacology, 2007, 2, 8-13.	4.1	13
297	Glycogen Synthase Kinase 3 Beta (GSK-3Î²) as a Therapeutic Target in NeuroAIDS. Journal of NeuroImmune Pharmacology, 2007, 2, 93-96.	4.1	39
298	The Journal of Neuroimmune Pharmacology Reaches Its Stride. Journal of NeuroImmune Pharmacology, 2007, 2, 129-130.	4.1	0
299	A Functional Transsulfuration Pathway in the Brain Links to Glutathione Homeostasis. Journal of Biological Chemistry, 2006, 281, 35785-35793.	3.4	198
300	Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 2006, 108, 2827-2835.	1.4	241
301	Chemokines and Their Receptors and the Neuropathogenesis of HIV-1 Infection. , 2006, , 45-80.		1
302	Debate: â€œIs Increasing Neuroinflammation Beneficial for Neural Repair?â€• Journal of NeuroImmune Pharmacology, 2006, 1, 195-211.	4.1	63
303	Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. Journal of NeuroImmune Pharmacology, 2006, 1, 340-350.	4.1	222
304	Neuroinflammation, oxidative stress, and the pathogenesis of Parkinsonâ€™s disease. Clinical Neuroscience Research, 2006, 6, 261-281.	0.8	305
305	Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain. Glia, 2006, 54, 81-93.	4.9	34
306	HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1Î². Glia, 2006, 54, 619-629.	4.9	92

#	Article	IF	Citations
307	Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis. Current HIV Research, 2006, 4, 279-291.	0.5	34
308	Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. Journal of Leukocyte Biology, 2006, 80, 1165-1174.	3.3	64
309	Monocyte Differentiation, Activation, and Mycobacterial Killing Are Linked to Transsulfuration-dependent Redox Metabolism. Journal of Biological Chemistry, 2006, 281, 38712-38720.	3.4	31
310	Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood, 2005, 106, 2382-2390.	1.4	144
311	Infections of the nervous system. Lancet Neurology, The, 2005, 4, 12-13.	10.2	25
312	Development of a rapid autopsy program for studies of brain immunity. Journal of Neuroimmunology, 2005, 163, 135-144.	2.3	19
313	Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects. Journal of Neuroimmunology, 2005, 163, 145-156.	2.3	26
314	Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations. Glia, 2005, 51, 161-172.	4.9	29
315	Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia, 2005, 52, 344-353.	4.9	54
316	Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotoxicity Research, 2005, 8, 25-50.	2.7	66
317	Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. Journal of Virology, 2005, 79, 2124-2132.	3.4	44
318	Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2005, 25, 8375-8385.	3.6	72
319	Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease. Journal of Neuroscience, 2005, 25, 1691-1700.	3.6	76
320	Overexpression of Monocyte Chemotactic Protein-1/CCL2 in Î²-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse Î²-Amyloid Deposition. American Journal of Pathology, 2005, 166, 1475-1485.	3.8	130
321	Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring. Current HIV Research, 2004, 2, 61-78.	0.5	36
322	Neuroregulatory Events Follow Adaptive Immune-Mediated Elimination of HIV-1-Infected Macrophages: Studies in a Murine Model of Viral Encephalitis. Journal of Immunology, 2004, 172, 7610-7617.	0.8	51
323	Memantine Protects Hippocampal Neuronal Function in Murine Human Immunodeficiency Virus Type 1 Encephalitis. Journal of Neuroscience, 2004, 24, 7194-7198.	3.6	71
324	Molecular Characterization of a Putative Antiretroviral Transcriptional Factor, OTK18. Journal of Immunology, 2004, 172, 381-391.	0.8	31

#	Article	IF	Citations
325	Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9435-9440.	7.1	299
326	Proteomic fingerprinting of human immunodeficiency virus type 1â€“associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	2.1	21
327	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	2.1	3
328	Proteomic fingerprinting of human immunodeficiency virus type 1?associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	2.1	19
329	Proteomic fingerprinting of HIV-1-infected human monocyte-derived macrophages: a preliminary report. Journal of Neuroimmunology, 2004, 147, 35-42.	2.3	19
330	TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia. Journal of Neuroimmunology, 2004, 148, 127-139.	2.3	55
331	OTK18 expression in brain mononuclear phagocytes parallels the severity of HIV-1 encephalitis. Journal of Neuroimmunology, 2004, 150, 186-198.	2.3	19
332	Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. Journal of Neuroimmunology, 2004, 157, 11-16.	2.3	33
333	Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. Journal of NeuroVirology, 2004, 10, 74-81.	2.1	17
334	Neuroprotective strategies for HIV-1 associated dementia. Neurotoxicity Research, 2004, 6, 503-521.	2.7	29
335	The Neuropathogenesis of HIV-1 Infection. , 2004, , 95-115.		8
336	Neural Immunity and Human Immunodeficiency Virus-1-Associated Dementia. , 2004, , 547-559.		1
337	C1qâ€“calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease. Journal of Neuroimmunology, 2003, 135, 62-71.	2.3	48
338	Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. Journal of Neuroimmunology, 2003, 138, 144-155.	2.3	83
339	Peripheral nerve induces macrophage neurotrophic activities: regulation of neuronal process outgrowth, intracellular signaling and synaptic function. Journal of Neuroimmunology, 2003, 142, 112-129.	2.3	32
340	Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: Links to HIV-1 dementia. Glia, 2003, 44, 47-56.	4.9	93
341	Inhibition of long-term potentiation by interleukin-8: Implications for human immunodeficiency virus-1-associated dementia. Journal of Neuroscience Research, 2003, 71, 600-607.	2.9	58
342	Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. Journal of Neuroscience Research, 2003, 73, 284-295.	2.9	87

#	Article	IF	Citations
343	Activation of NR1a/NR2B receptors by monocyte-derived macrophage secretory products: implications for human immunodeficiency virus type one-associated dementia. Neuroscience Letters, 2003, 341, 246-250.	2.1	15
344	Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. Journal of Leukocyte Biology, 2003, 74, 691-701.	3.3	152
345	Non-neuronal interactions in HIV-1-associated dementia. Advances in Molecular and Cell Biology, 2003, 31, 901-920.	0.1	1
346	Neuroprotective Activities of Sodium Valproate in a Murine Model of Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2003, 23, 9162-9170.	3.6	113
347	Neuroimaging and Proteomic Tracking of Neurodegeneration in MPTPâ€Treated Mice. Annals of the New York Academy of Sciences, 2003, 991, 319-321.	3.8	2
348	Generation of Cytotoxic T Cells Against Virus-Infected Human Brain Macrophages in a Murine Model of HIV-1 Encephalitis. Journal of Immunology, 2002, 168, 3941-3949.	0.8	69
349	Murine Models for Human Immunodeficiency Virus Type 1-Associated Dementia: The Development of New Treatment Testing Paradigms. Journal of NeuroVirology, 2002, 8, 49-52.	2.1	31
350	HIV-1â€“Associated Dementia: A Metabolic Encephalopathy Perpetrated by Virus-Infected and Immune-Competent Mononuclear Phagocytes. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S43-S54.	2.1	134
351	Impaired Spatial Cognition and Synaptic Potentiation in a Murine Model of Human Immunodeficiency Virus Type 1 Encephalitis. Journal of Neuroscience, 2002, 22, 2096-2105.	3.6	73
352	Mononuclear phagocyte biophysiology influences brain transendothelial and tissue migration: implication for HIV-1-associated dementia. Journal of Neuroimmunology, 2002, 122, 40-54.	2.3	26
353	Neural Immunity: Friend or Foe?. Journal of NeuroVirology, 2002, 8, 474-479.	2.1	113
354	Macrophages, chemokines and neuronal injury in HIV-1-associated dementia. Cellular and Molecular Biology, 2002, 48, 137-50.	0.9	27
355	HIV-1-associated dementia: a basic science and clinical perspective. Aids Reader, 2002, 12, 358-68.	0.3	34
356	HIV-1 infected and immune competent mononuclear phagocytes induce quantitative alterations in neuronal dendritic arbor: Relevance for HIV-1-associated dementia. Neurotoxicity Research, 2001, 3, 443-459.	2.7	36
357	HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. Neurotoxicity Research, 2001, 3, 461-484.	2.7	35
358	The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia. Journal of Neuroimmunology, 2001, 120, 112-128.	2.3	43
359	Mononuclear Phagocyte Differentiation, Activation, and Viral Infection Regulate Matrix Metalloproteinase Expression: Implications for Human Immunodeficiency Virus Type 1-Associated Dementia. Journal of Virology, 2001, 75, 6572-6583.	3.4	82
360	Plasma Levels of Soluble CD14 and Tumor Necrosis Factorâ€Î± Type II Receptor Correlate with Cognitive Dysfunction during Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 2001, 184, 699-706.	4.0	85

#	Article	IF	Citations
361	Regulation of Human Immunodeficiency Virus Type 1 Infection, Î²-Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry. Journal of Virology, 2001, 75, 4308-4320.	3.4	44
362	Model Systems for Assessing Cognitive Function: Implications for HIV-1 Infection and Drugs of Abuse. , 2001, 493, 7-27.		4
363	Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System. Journal of Immunology, 2000, 164, 1333-1339.	0.8	186
364	Cytokine-Stimulated, But Not HIV-Infected, Human Monocyte-Derived Macrophages Produce Neurotoxic Levels of <scp>l</scp>-Cysteine. Journal of Immunology, 2000, 164, 4265-4270.	0.8	89
365	Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. Journal of Leukocyte Biology, 1999, 65, 416-427.	3.3	76
366	Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products. AIDS Research and Human Retroviruses, 1999, 15, 57-63.	1.1	23
367	HIV-Associated Dementia: New Insights into Disease Pathogenesis and Therapeutic Interventions. AIDS Patient Care and STDs, 1999, 13, 153-163.	2.5	42
368	The blood-brain barrier: a defensive shield or a perpetrator of microbial invasion?. Journal of NeuroVirology, 1999, 5, 533-537.	2.1	3
369	Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. Journal of Neuroimmunology, 1999, 98, 185-200.	2.3	299
370	Microglial and Astrocyte Chemokines Regulate Monocyte Migration through the Blood-Brain Barrier in Human Immunodeficiency Virus-1 Encephalitis. American Journal of Pathology, 1999, 155, 1599-1611.	3.8	266
371	The cellular immunology of multiple sclerosis. Journal of Leukocyte Biology, 1999, 65, 444-452.	3.3	52
372	Innate and acquired immunity in neurodegenerative disorders. Journal of Leukocyte Biology, 1999, 65, 407-408.	3.3	17
373	Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. Journal of NeuroVirology, 1999, 5, 519-528.	2.1	40
374	Lymphotropic Virions Affect Chemokine Receptor-Mediated Neural Signaling and Apoptosis: Implications for Human Immunodeficiency Virus Type 1-Associated Dementia. Journal of Virology, 1999, 73, 8256-8267.	3.4	125
375	Suppression of Inflammatory Neurotoxins by Highly Active Antiretroviral Therapy in Human Immunodeficiency Virusâ€Associated Dementia. Journal of Infectious Diseases, 1998, 178, 1000-1007.	4.0	169
376	Human Immunodeficiency Virus Neurotropism: an Analysis of Viral Replication and Cytopathicity for Divergent Strains in Monocytes and Microglia. Journal of Virology, 1998, 72, 3340-3350.	3.4	94
377	Role of the Î²-Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia. Journal of Virology, 1998, 72, 3351-3361.	3.4	146
378	Dexamethasone Therapy Worsens the Neuropathology of Human Immunodeficiency Virus Type 1 Encephaliti in SCID Mice. Journal of Infectious Diseases, 1997, 175, 1368-1381.	4.0	29

#	Article	IF	Citations
379	The HIV-1 associated dementia complex. Current Opinion in Neurology, 1997, 10, 319-326.	3.6	72
380	An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. Journal of NeuroVirology, 1997, 3, 401-416.	2.1	121
381	Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia. Journal of Leukocyte Biology, 1997, 62, 100-106.	3.3	54
382	The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes. Journal of NeuroVirology, 1996, 2, 111-117.	2.1	39
383	Regulation and Characterization of the Interferon-Î± Present in Patients with Advanced Human Immunodeficiency Virus Type 1 Disease. Journal of Interferon and Cytokine Research, 1996, 16, 127-137.	1.2	14
384	Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Trends in Immunology, 1995, 16, 441-448.	7.5	110
385	The development of animal model systems for HIV-1 encephalitis and its associated dementia. Journal of NeuroVirology, 1995, 1, 229-243.	2.1	38
386	Utility of cerebral proton magnetic resonance spectroscopy in differential diagnosis of HIV-related dementia. Journal of NeuroVirology, 1995, 1, 268-274.	2.1	11
387	Dementia Associated with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1995, 332, 934-940.	27.0	476
388	Prospective Utility of Cerebral Proton Magnetic Resonance Spectroscopy in Monitoring HIV Infection and Its Associated Neurological Impairment. AIDS Research and Human Retroviruses, 1994, 10, 977-982.	1.1	60
389	An experimental model system for HIV-1-induced brain injury. Advances in Neuroimmunology, 1994, 4, 189-193.	1.8	59
390	The neuropathogenesis of HIV-1 infection. Journal of Leukocyte Biology, 1994, 56, 389-398.	3.3	247
391	Cellular and viral determinants that regulate HIV-1 infection in macrophages. Journal of Leukocyte Biology, 1994, 56, 278-288.	3.3	44
392	Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms. Annals of Neurology, 1993, 33, 429-436.	5.3	377
393	No Direct Neuronotoxicity by HIV-1 Virions or Culture Fluids from HIV-1-Infected T Cells or Monocytes. AIDS Research and Human Retroviruses, 1992, 8, 495-503.	1.1	49
394	Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection. AIDS Research and Human Retroviruses, 1992, 8, 199-207.	1.1	121
395	Regulation of Cytokine and Viral Gene Expression in Monocytes Infected with the Human Immunodeficiency Virus. Pathobiology, 1991, 59, 209-213.	3.8	9
396	HIV Replication and Persistence in Human Gastrointestinal Cells Cultured In Vitro. Journal of Leukocyte Biology, 1991, 49, 499-504.	3.3	24

#	Article	IF	Citations
397	Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules. Immunology Letters, 1991, 30, 219-227.	2.5	42
398	Macrophages and the human immunodeficiency virus. Trends in Immunology, 1990, 11, 217-223.	7.5	173
399	Restriction of HIV Replication in Infected T Cells and Monocytes by Interferon-Î±. AIDS Research and Human Retroviruses, 1990, 6, 1045-1049.	1.1	63
400	Macrophages as Susceptible Targets for HIV Infection, Persistent Viral Reservoirs in Tissue, and Key Immunoregulatory Cells that Control Levels of Virus Replication and Extent of Disease. AIDS Research and Human Retroviruses, 1990, 6, 967-971.	1.1	112
401	Infection of Human Gastrointestinal Cells by HIV-1. AIDS Research and Human Retroviruses, 1990, 6, 1409-1415.	1.1	58
402	Role of Mononuclear Phagocytes in the Pathogenesis of Human Immunodeficiency Virus Infection. Annual Review of Immunology, 1990, 8, 169-194.	21.8	279
403	Development of an in Vitro Human Monocyte-Derived Macrophage-Based System for Drug Screening against HIV-1. Annals of the New York Academy of Sciences, 1990, 616, 597-598.	3.8	0
404	The Human Immunodeficiency Virus Long Terminal Repeat Is Preferentially Expressed in Langerhans Cells in Transgenic Mice. AIDS Research and Human Retroviruses, 1989, 5, 421-430.	1.1	69
405	Immunopathogenesis of human immunodeficiency virus infection in the central nervous system. Annals of Neurology, 1988, 23, S78-S81.	5.3	34
406	Effects of colony stimulating factors on the interaction of monocytes and the human immunodeficiency virus. Immunology Letters, 1988, 19, 193-198.	2.5	25
407	Molecular pathogenesis of human immunodeficiency virus infection. Gene Analysis Techniques, 1988, 5, 41-53.	1.0	4
408	A double labeling technique for performing immunocytochemistry and in situ hybridization in virus infected cell cultures and tissues. Journal of Virological Methods, 1985, 11, 93-103.	2.1	77
409	Selection of a fixative for identifying T cell subsets, B cells, and macrophages in paraffin-embedded mouse spleen. Journal of Immunological Methods, 1983, 65, 137-145.	1.4	90
410	Chemokines and the Neuropathogenesis of HIV-1 Infection. , 0, , 151-171.		1